Literature DB >> 15539710

Regional differences in emphysema scores and BAL glutathione levels in HIV-infected individuals.

Philip T Diaz1, Mark D Wewers, Mark King, Joyce Wade, Judy Hart, Thomas L Clanton.   

Abstract

STUDY
OBJECTIVES: Evidence exists that HIV-seropositive individuals may be at increased risk for the development of precocious pulmonary emphysema. HIV infection is also associated with antioxidant deficiency in both the serum and lungs, and it is therefore possible that increased oxidant stress may contribute to parenchymal lung injury occurring in the setting of HIV. We sought to determine the regional distribution of emphysema and regional distribution of glutathione (GSH) concentrations among HIV-seropositive subjects with emphysema.
DESIGN: Cross-sectional evaluation of a prospective, longitudinal study.
SETTING: University teaching hospital. SUBJECTS/MEASUREMENTS: HIV-seropositive subjects without AIDS-related pulmonary complications participating in a descriptive study of lung biology in HIV-seropositive individuals. Emphysema scoring and evaluation of emphysema lobar distribution was performed among 40 subjects with emphysema. Eleven subjects underwent BAL of the right middle lobe (RML) and right upper lobe (RUL) with measurement of epithelial lining fluid (ELF) GSH in each lobe.
RESULTS: We found that the mean emphysema scores were much higher in the upper lobes compared to the rest of the lung. Mean GSH levels were significantly greater in the RUL compared to the RML. The regional differences were present in both smokers and nonsmokers.
CONCLUSIONS: We conclude that in the setting of HIV, emphysema is more prominent and lung GSH concentrations are higher in the upper lobes. We hypothesize that the increased GSH may represent a compensatory response to increased oxidant stress in the upper lobes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15539710     DOI: 10.1378/chest.126.5.1439

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  8 in total

1.  Risk Factors Associated With Quantitative Evidence of Lung Emphysema and Fibrosis in an HIV-Infected Cohort.

Authors:  Joseph K Leader; Kristina Crothers; Laurence Huang; Mark A King; Alison Morris; Bruce W Thompson; Sonia C Flores; Michael B Drummond; William N Rom; Philip T Diaz
Journal:  J Acquir Immune Defic Syndr       Date:  2016-04-01       Impact factor: 3.731

2.  Chronic obstructive pulmonary disease: an emerging comorbidity in HIV-infected patients in the HAART era?

Authors:  G Madeddu; A G Fois; G M Calia; S Babudieri; V Soddu; F Becciu; M L Fiori; V Spada; C Lovigu; M Mannazzu; A Caddeo; B Piras; P Pirina; M S Mura
Journal:  Infection       Date:  2012-09-13       Impact factor: 3.553

Review 3.  An official ATS workshop report: Emerging issues and current controversies in HIV-associated pulmonary diseases.

Authors:  Alison Morris; Kristina Crothers; James M Beck; Laurence Huang
Journal:  Proc Am Thorac Soc       Date:  2011-03

4.  Impact of HIV infection on α1-antitrypsin in the lung.

Authors:  Sarah E Stephenson; Carole L Wilson; Kristina Crothers; Engi F Attia; Cherry Wongtrakool; Irina Petrache; Lynn M Schnapp
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-12-14       Impact factor: 5.464

Review 5.  Pulmonary disease in HIV-infected adults in the era of antiretroviral therapy.

Authors:  Meghan E Fitzpatrick; Ken M Kunisaki; Alison Morris
Journal:  AIDS       Date:  2018-01-28       Impact factor: 4.177

Review 6.  Chronic obstructive pulmonary disease in HIV.

Authors:  Katerina Byanova; Ken M Kunisaki; Joshua Vasquez; Laurence Huang
Journal:  Expert Rev Respir Med       Date:  2020-11-23       Impact factor: 3.772

Review 7.  Maintaining lung health with longstanding HIV.

Authors:  Paul Collini; Alison Morris
Journal:  Curr Opin Infect Dis       Date:  2016-02       Impact factor: 4.915

8.  Anti-retroviral therapy is associated with decreased alveolar glutathione levels even in healthy HIV-infected individuals.

Authors:  Sushma K Cribbs; David M Guidot; Greg S Martin; Jeffrey Lennox; Lou Ann Brown
Journal:  PLoS One       Date:  2014-02-12       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.